Source: British Journal of Cancer. Unidade: FM
Subjects: BIOMARCADORES, NEOPLASIAS (PREVENÇÃO E CONTROLE)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
JÜRGENSMEIER, J. M. et al. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. British Journal of Cancer, v. 108, n. 6, p. 1316-1323, 2013Tradução . . Disponível em: https://doi.org/10.1038/bjc.2013.79. Acesso em: 21 maio 2024.APA
Jürgensmeier, J. M., Schmoll, H. -J., Robertson, J. D., Brooks, L., Taboada, M., Morgan, S. R., et al. (2013). Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. British Journal of Cancer, 108( 6), 1316-1323. doi:10.1038/bjc.2013.79NLM
Jürgensmeier JM, Schmoll H-J, Robertson JD, Brooks L, Taboada M, Morgan SR, Wilson D, Hoff PM. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy [Internet]. British Journal of Cancer. 2013 ; 108( 6): 1316-1323.[citado 2024 maio 21 ] Available from: https://doi.org/10.1038/bjc.2013.79Vancouver
Jürgensmeier JM, Schmoll H-J, Robertson JD, Brooks L, Taboada M, Morgan SR, Wilson D, Hoff PM. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy [Internet]. British Journal of Cancer. 2013 ; 108( 6): 1316-1323.[citado 2024 maio 21 ] Available from: https://doi.org/10.1038/bjc.2013.79
